Laboratory Assay in Determining Cancer Resistance in Patients With Metastatic Cancer and in Healthy Participants
Pilot Study of Cancer Resistance in Humans
RATIONALE: Studying samples of blood and tissue in the laboratory from patients with cancer and from healthy participants may help doctors learn more about cancer.
PURPOSE: This laboratory study is looking at an assay in determining cancer resistance in patients with metastatic cancer and in healthy participants.
研究概览
详细说明
OBJECTIVES:
- Optimize and standardize the in vitro cell kill assay using human white blood cells and human cancer cell lines from patients with metastatic cancer and from healthy participants.
- Determine the results of the in vitro cell kill assay in patients with metastatic cancer and in healthy participants with no history of cancer.
OUTLINE: This is a pilot study.
Peripheral blood is obtained from healthy participants and from cancer patients. Tissue is collected from archived samples. White blood cells are obtained from tissue and blood samples and are assessed by the in vitro cell kill assay.
PROJECTED ACCRUAL: A total of 24 patients and 24 healthy participants will be accrued for this study.
研究类型
注册 (实际的)
联系人和位置
学习地点
-
-
North Carolina
-
Winston-Salem、North Carolina、美国、27157-1096
- Wake Forest University Comprehensive Cancer Center
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
描述
Inclusion Criteria:
-Meets 1 of the following criteria:
Diagnosis of metastatic cancer including, but not limited to, any of the following:
- Stage IV non-small cell lung cancer
- Extensive-stage small cell lung cancer
- Metastatic testicular cancer
- Stage IV breast carcinoma
- Stage III or IV ovarian carcinoma
- Stage IV endometrial carcinoma
- Stage IV prostate carcinoma
- Stage IV colorectal or pancreatic cancer
- Stage IV renal cancer
- Stage III or IV non-Hodgkin's lymphoma
- Stage IV bladder cancer
- Stage III multiple myeloma (Salmon-Durie staging)
- Metastatic melanoma
- Metastatic sarcoma
Healthy participant, meeting the following criteria:
- No prior cancer
- Over 50 years of age
Exclusion Criteria:
- Serious medical or psychiatric condition that would preclude study compliance
- Chemotherapy or radiotherapy within the past 3 months (patient)
- Prior immunosuppressive therapy or radiotherapy for any disease (healthy participant)
学习计划
研究是如何设计的？
设计细节
研究衡量的是什么？
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
Cell killing ability (positive or negative)
大体时间：Day 180
|
Day 180
|
|
Percentage of cells killed
大体时间：Day 180
|
Day 180
|
合作者和调查者
调查人员
- 学习椅：Zheng Cui, PhD、Wake Forest University Health Sciences
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
关键字
- IV期肾细胞癌
- III期恶性睾丸生殖细胞肿瘤
- IV期乳腺癌
- 广泛期小细胞肺癌
- IV期膀胱癌
- IV期前列腺癌
- IV期非小细胞肺癌
- 未指定的成人实体瘤，具体方案
- IV期直肠癌
- IV期结肠癌
- III期卵巢上皮癌
- IV期卵巢上皮癌
- III期成人弥漫性大细胞淋巴瘤
- III期成人免疫母细胞大细胞淋巴瘤
- III期成人伯基特淋巴瘤
- IV期3级滤泡性淋巴瘤
- IV期成人弥漫性大细胞淋巴瘤
- IV期成人免疫母细胞大细胞淋巴瘤
- IV期成人Burkitt淋巴瘤
- IV期黑色素瘤
- IV期胰腺癌
- 华氏巨球蛋白血症
- III期成人弥漫性小裂细胞淋巴瘤
- III期成人弥漫性混合细胞淋巴瘤
- IV 期 1 级滤泡性淋巴瘤
- IV 期 2 级滤泡性淋巴瘤
- IV期成人弥漫性小裂细胞淋巴瘤
- IV期成人弥漫性混合细胞淋巴瘤
- III期套细胞淋巴瘤
- IV期套细胞淋巴瘤
- III期多发性骨髓瘤
- III期小淋巴细胞淋巴瘤
- III期边缘区淋巴瘤
- IV期小淋巴细胞淋巴瘤
- IV期边缘区淋巴瘤
- 黏膜相关淋巴组织结外边缘区B细胞淋巴瘤
- 淋巴结边缘区B细胞淋巴瘤
- 脾边缘区淋巴瘤
- IV期子宫内膜癌
- 原发性中枢神经系统非霍奇金淋巴瘤
- III期皮肤T细胞非霍奇金淋巴瘤
- IV 期皮肤 T 细胞非霍奇金淋巴瘤
- III期成人淋巴母细胞淋巴瘤
- IV期成人淋巴母细胞淋巴瘤
- III期成人T细胞白血病/淋巴瘤
- IV 期成人 T 细胞白血病/淋巴瘤
- 眼内淋巴瘤
- 血管免疫母细胞性T细胞淋巴瘤
- 间变性大细胞淋巴瘤
- III 期蕈样肉芽肿/Sezary 综合征
- IV 期蕈样肉芽肿/Sezary 综合征
- 成人 III 级淋巴瘤样肉芽肿病
- 成人鼻型结外 NK/T 细胞淋巴瘤
- 皮肤B细胞非霍奇金淋巴瘤
- IV期成人软组织肉瘤
- IV期子宫肉瘤
- 卵巢肉瘤
- 转移性骨肉瘤
其他研究编号
- CCCWFU 95A05
- P30CA012197 (美国 NIH 拨款/合同)
- CCCWFU-99A05
- CCCWFU-BG05-342
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.